CCRM is a public-private partnership with a mission of being an industry builder that generates economic and health benefits from Canada’s strengths in the science of regenerative medicine, and cell and gene therapies. It’s doing so by building specialized manufacturing infrastructure and early-stage to clinical manufacturing capabilities through OmniaBio, a subsidiary of CCRM; investing in and launching new ventures like Notch Therapeutics; and offering in-house training as well as through our partnership in the Canadian Advanced Therapies Training Institute (CATTI). Hear from a parent who believes gene therapy is the future of medicine and Canada can lead in this field. See visuals of CCRM’s facility in Toronto’s MaRS Discovery District, and OmniaBio’s site plans for Hamilton’s McMaster Innovation Park.
